The loss of this “metabolic flexibility” would be an early sign of adipocyte dysfunction and would result in excessive postprandial lipemia, enhanced FFA, and lipid uptake by the liver and adipose tissue, (56, 57) ultimately leading to NAFLD, visceral obesity, and lower fasting adiponectin levels. The gene discussed is ADIPOQ; the disease is metabolic dysfunction-associated steatotic liver disease.